Papillary Carcinoma of Breast: Clinicopathological Characteristics, Management, and Survival.

IF 1.6 Q4 ONCOLOGY

International Journal of Breast Cancer Pub Date : 2022-10-13 eCollection Date: 2022-01-01 DOI:10.1155/2022/5427837

Bushra Rehman, Anam Mumtaz, Barka Sajjad, Namra Urooj, Sameen Mohtasham Khan, M Toqeer Zahid, Huma Mannan, M Zulqarnain Chaudhary, Amina Khan, M Asad Parvaiz

{"title":"Papillary Carcinoma of Breast: Clinicopathological Characteristics, Management, and Survival.","authors":"Bushra Rehman, Anam Mumtaz, Barka Sajjad, Namra Urooj, Sameen Mohtasham Khan, M Toqeer Zahid, Huma Mannan, M Zulqarnain Chaudhary, Amina Khan, M Asad Parvaiz","doi":"10.1155/2022/5427837","DOIUrl":null,"url":null,"abstract":"Objective: To study clinicopathological features, treatment strategies, and prognosis of papillary carcinoma of breast. Material and Methods. Data from 58 patients were retrospectively reviewed from January 2010 to December 2016. Four types of papillary carcinoma (on final resected specimen) were included, i.e., invasive papillary carcinoma (IPC), intracystic (encapsulated) papillary carcinoma (EPC), solid papillary carcinoma (SPC), and papillary DCIS (ductal carcinoma in situ). Various features of the four types were observed and compared.Results: Of the 58 patients, 8 were males (13.7%). The mean age at presentation was 61 years; the mean tumor size was 33 mm. The frequency of each histological type was as follows: IPC (n = 22/38%), EPC (n = 22/38%), SPC (n = 12/20.6%), and papillary DCIS (n = 2/3.4%). Only two patients were ER negative (both IPC). HER-2 Neu was positive in 3 patients only, out of which 2 died of progressive disease (one EPC and one IPC). LN metastasis was present in 3 (5%) patients (one in each of 1st three types) and only one died of bone metastasis that was also Her-2Neu positive. All patients underwent upfront surgery except two patients who had synchronous IDC on the contralateral side. Breast conservation surgery (BCS) was performed in 34 (58.6%) and mastectomy in 22 (37.9%) patients. 13 patients did not undergo invasive axillary staging; the rest of 43 (74%) patients did (32 sentinel biopsy and 11 axillary dissection). Chemotherapy was given to 18 patients (31%), mostly to IPC (n = 12). Only 2 patients had bone metastasis (one was IPC and one EPC). Cancer-related death was observed in 3 patients. For all groups combined, 5-year OS was 98% and DFS was 92%.Conclusion: Overall, papillary carcinoma of the breast has an excellent prognosis, even though less intense treatment modalities were used. It is still difficult to define the optimum management and avoid overtreatment, given the limited data in the literature.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584724/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/5427837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Objective: To study clinicopathological features, treatment strategies, and prognosis of papillary carcinoma of breast. Material and Methods. Data from 58 patients were retrospectively reviewed from January 2010 to December 2016. Four types of papillary carcinoma (on final resected specimen) were included, i.e., invasive papillary carcinoma (IPC), intracystic (encapsulated) papillary carcinoma (EPC), solid papillary carcinoma (SPC), and papillary DCIS (ductal carcinoma in situ). Various features of the four types were observed and compared.

Results: Of the 58 patients, 8 were males (13.7%). The mean age at presentation was 61 years; the mean tumor size was 33 mm. The frequency of each histological type was as follows: IPC (n = 22/38%), EPC (n = 22/38%), SPC (n = 12/20.6%), and papillary DCIS (n = 2/3.4%). Only two patients were ER negative (both IPC). HER-2 Neu was positive in 3 patients only, out of which 2 died of progressive disease (one EPC and one IPC). LN metastasis was present in 3 (5%) patients (one in each of 1st three types) and only one died of bone metastasis that was also Her-2Neu positive. All patients underwent upfront surgery except two patients who had synchronous IDC on the contralateral side. Breast conservation surgery (BCS) was performed in 34 (58.6%) and mastectomy in 22 (37.9%) patients. 13 patients did not undergo invasive axillary staging; the rest of 43 (74%) patients did (32 sentinel biopsy and 11 axillary dissection). Chemotherapy was given to 18 patients (31%), mostly to IPC (n = 12). Only 2 patients had bone metastasis (one was IPC and one EPC). Cancer-related death was observed in 3 patients. For all groups combined, 5-year OS was 98% and DFS was 92%.

Conclusion: Overall, papillary carcinoma of the breast has an excellent prognosis, even though less intense treatment modalities were used. It is still difficult to define the optimum management and avoid overtreatment, given the limited data in the literature.

查看原文本刊更多论文

乳腺乳头状癌:临床病理特征，管理和生存。

目的:探讨乳腺乳头状癌的临床病理特点、治疗策略及预后。材料和方法。对2010年1月至2016年12月58例患者的数据进行回顾性分析。包括四种类型的乳头状癌(最终切除标本)，即浸润性乳头状癌(IPC)，囊内(包封)乳头状癌(EPC)，实体性乳头状癌(SPC)和乳头状DCIS(导管原位癌)。观察并比较四种类型的各种特征。结果:58例患者中，男性8例(13.7%)。发病时平均年龄61岁;平均肿瘤大小为33 mm。各组织学类型的发生率分别为:IPC (n = 22/38%)、EPC (n = 22/38%)、SPC (n = 12/20.6%)、乳头状DCIS (n = 2/3.4%)。仅有2例患者ER阴性(均为IPC)。只有3例患者HER-2 Neu阳性，其中2例死于疾病进展(1例EPC和1例IPC)。3例(5%)患者出现淋巴结转移(前三种类型各1例)，仅有1例死于Her-2Neu阳性的骨转移。除2例对侧同步IDC患者外，所有患者均行术前手术。保乳手术34例(58.6%)，乳房切除术22例(37.9%)。13例未行浸润性腋窝分期;其余43例(74%)患者进行了检查(32例前哨活检和11例腋窝清扫)。化疗18例(31%)，主要为IPC (n = 12)。仅有2例发生骨转移(1例IPC, 1例EPC)。3例患者出现肿瘤相关死亡。所有组的5年OS为98%，DFS为92%。结论:总体而言，即使采用较低强度的治疗方式，乳腺乳头状癌的预后也很好。鉴于文献资料有限，确定最佳管理和避免过度治疗仍然很困难。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Breast Cancer ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.